21 April 2021
The Adaptive Platform Trial for Community-Acquired Pneumonia, REMAP-CAP, launched its third video. The video shows the global and diverse of REMAP-CAP.
REMAP-CAP is making a difference in the way clinical research is done. By using a modern and innovative research design, by realizing global collaborations and by integrating research into clinical care. The REMAP-CAP family continues to grow, with more and more researchers, patients, pharmacists, research nurses, and coordinators joining in every day.
Since the COVID-19 outbreak, the platform has extended its domains to investigate new treatments specifically for COVID-19 patients on the ICU and the ward. With the ability to test various interventions simultaneously within multiple therapeutic domains, REMAP-CAP can determine the best treatment regimen instead of one single treatment. It also allows for optimal use of data and provides information about interactions between domains and interventions.
REMAP-CAP in Europe
The study is currently active in 13 European countries with 205 sites. So far, 4.871 COVID-19 patients and 225 CAP patients have been randomized. In this first year, it has investigated 31 potential treatments for COVID. This has led to multiple platform conclusions, that have changed clinical care of hospitalized patients with COVID-19 immediately.
REMAP-CAP published its first results in JAMA on the effect of Hydrocortisone on organ-support free days in critically-ill COVID-19 patients, and in the New England Journal of Medicine showing treatment with Tocilizumab and Sarilumab improved outcomes in critically-ill COVID-19 patients receiving organ support in the ICU. We aim to continue to investigate repurposed as well as newly developed drugs, which can all be done in the trial. We also aim to collaborate with other EU and global groups to find the best treatments for patients fast.
Are you or your hospital interested in or want to join REMAP-CAP? Write to us!